Tempus AI dives after-hours despite strong Q3 numbers
The medical diagnostic company, which is developing new AI-driven tests, has at times been a favorite of retail investors.
Tempus AI, a company that captured the attention of retail shareholders and surged to a valuation of more than $15 billion in spite of persistent losses, reported better-than-expected Q3 results after the close of trading on Tuesday.
But investors seemed unimpressed, as the stock — which already fell almost 5% during the regular session — dove another 6.5% after-hours.
The cancer diagnostics and genetic sequencing company, whose CEO we interviewed earlier this year, reported:
Sales of $334.2 million vs. the $328.7 million estimated by 13 Wall Street analysts whose forecasts FactSet tracks.
An adjusted loss per share of $0.11 vs. the $0.17 expected on Wall Street.
Full-year 2025 guidance of ~$1.265 billion vs. the $1.259 billion Wall Street consensus estimate.
Tempus AI went public in June 2024, and was up more than 150% in 2025 through the close of the New York trading session Tuesday.
